Levodopa/Carbidopa/Entacapone Mylan (Entacapone, Levodopa, Carbidopa Monohydrate)

Levodopa/Carbidopa/Entacapone is employed within the Parkinson's disease treatment pathway to enhance levodopa efficacy.

• Parkinson's disease (adjunct to levodopa): improves overall motor control and reduces bradykinesia.
• Parkinson's disease (fluctuating symptoms): decreases the duration and frequency of "off" periods.
• Parkinson's disease (long‑term therapy): prolongs the therapeutic effect of levodopa and helps maintain consistent symptom control.

• Levodopa is a dopamine precursor that crosses the blood‑brain barrier and is converted to dopamine in the central nervous system. Carbidopa inhibits peripheral aromatic L‑amino acid decarboxylase, preventing premature conversion of levodopa and increasing its central availability. Entacapone blocks catechol‑O‑methyltransferase (COMT), reducing peripheral levodopa metabolism and extending its plasma half‑life, thereby sustaining dopaminergic stimulation.

Levodopa/Carbidopa/Entacapone may cause a range of adverse reactions.

Common Side Effects

• Nausea: mild to moderate gastrointestinal upset.
• Vomiting: occasional emesis, especially after dose initiation.
• Dizziness: transient light‑headedness, often orthostatic.
• Headache: mild to moderate tension‑type pain.
• Orthostatic hypotension: drop in blood pressure upon standing.
• Insomnia: difficulty initiating or maintaining sleep.

Serious or Rare Side Effects

• Severe hypotension: marked blood pressure decline requiring medical attention.
• Cardiac arrhythmias: irregular heart rhythms, potentially life‑threatening.
• Neuroleptic malignant syndrome: rare but critical hyperthermic reaction.
• Severe allergic reactions: rash, angioedema, or anaphylaxis.
• Dyskinesia: involuntary movements, especially with high levodopa exposure.
• Hallucinations: visual or auditory disturbances, often in older patients.

When prescribing Levodopa/Carbidopa/Entacapone, clinicians should consider several safety measures.

• Dose titration: adjust gradually based on clinical response and tolerability.
• Renal impairment: monitor renal function and consider dose modification.
• Hepatic impairment: use with caution; assess liver enzymes regularly.
• Psychiatric history: watch for emergence of hallucinations or psychosis.
• Concomitant MAO‑B inhibitors: avoid due to risk of hypertensive crisis.
• Store at room temperature: keep in original packaging, protect from moisture and direct sunlight.

Levodopa/Carbidopa/Entacapone can interact with several drug classes, requiring careful management.

Major Interactions (Avoid)

• Non‑selective MAO inhibitors: may precipitate hypertensive emergencies.
• Anticholinergic agents: can diminish the therapeutic benefit of dopaminergic therapy.
• Antihypertensive drugs: additive blood‑pressure lowering effect may cause symptomatic hypotension.

Moderate Interactions (Monitor Closely)

• SSRIs/SNRIs: potential for serotonin syndrome when combined.
• Iron supplements: reduce levodopa absorption; separate dosing by at least two hours.
• High‑protein meals: may interfere with levodopa transport across the gut and blood‑brain barrier.